RUNX1 (AML-1) and RUNX2 (AML-3) cooperate with prostate-derived Ets factor to activate transcription from the PSA upstream regulatory region

Journal of Cellular Biochemistry

Volumn 97, Issue 1, 2006, Pages 1-17

  Fowler, Marcie ^a   Borazanci, Erkut ^a   McGhee, Laura ^a   Pylant, Shannon Walls ^b   Williams, B Jill ^a,b   Glass, Jonathan ^a,b   Davis, J Nathan ^a   Meyers, Shari ^a,c  

^a LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^b Louisiana State University School of Medicine Shreveport   (United States)

^c LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

PDEF; Prostate cancer; Prostate specific antigen; RUNX; Transcription

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; TRANSCRIPTION FACTOR ETS; TRANSCRIPTION FACTOR RUNX1; TRANSCRIPTION FACTOR RUNX2; TRANSCRIPTION FACTOR RUNX3;

ARTICLE; BONE DEVELOPMENT; CANCER CELL CULTURE; CELL CYCLE; CELL DIFFERENTIATION; CELL FUNCTION; CELL IMMORTALIZATION; CHROMATIN IMMUNOPRECIPITATION; CONSENSUS SEQUENCE; CONTROLLED STUDY; GENE EXPRESSION; GENE EXPRESSION REGULATION; GENE IDENTIFICATION; HEMATOPOIESIS; HUMAN; HUMAN CELL; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE EPITHELIUM; PROTEIN EXPRESSION; PROTEIN FUNCTION; REGULATORY MECHANISM; TRANSCRIPTION INITIATION;

BASE SEQUENCE; CELL LINE, TUMOR; CHROMATIN IMMUNOPRECIPITATION; CORE BINDING FACTOR ALPHA 2 SUBUNIT; CORE BINDING FACTOR ALPHA 3 SUBUNIT; DNA PRIMERS; FEMALE; GENE EXPRESSION REGULATION; HUMANS; MALE; MUTAGENESIS, SITE-DIRECTED; PROMOTER REGIONS (GENETICS); PROSTATE-SPECIFIC ANTIGEN; PROTO-ONCOGENE PROTEINS C-ETS; REGULATORY SEQUENCES, NUCLEIC ACID; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TRANSCRIPTION, GENETIC;

EID: 30044434221     PISSN: 07302312     EISSN: None     Source Type: Journal    
DOI: 10.1002/jcb.20664     Document Type: Article

References (39)

1. Bergwitz C, Prochnau A, Mayr B, Kramer FJ, Rittierodt M, Berten HL, Hausamen JE, Brabant G. 2001. Identification of novel CBFA1/RUNX2 mutations causing cleidocranial dysplasia. J Inherit Metab Dis 24:648-656.
2. Brubaker KD, Vessella RL, Brown LG, Corey E. 2003. Prostate cancer expression of runt-domain transcription factor Runx2, a key regulator of osteoblast differentiation and function. Prostate 56:13-22.
3. Chen C, Okayama H. 1987. High-efficiency transformation of mammalian cells by plasmid DNA. Mol Cell Biol 7: 2745-2752.
4. Chen CD, Sawyers CL. 2002. NF-kappa B activates prostate-specific antigen expression and is upregulated in androgen-independent prostate cancer. Mol Cell Biol 22:2862-2870.
5. Chen H, Nandi AK, Li X, Bieberich CJ. 2002. NKX-3.1 interacts with prostate-derived Ets factor and regulates the activity of the PSA promoter. Cancer Res 62:338-340.
6. Cleutjens KB, van Eekelen CC, van der Korput HA, Brinkmann AO, Trapman J. 1996. Two androgen response regions cooperate in steroid hormone regulated activity of the prostate-specific antigen promoter. J Biol Chem 271:6379-6388.
7. Cleutjens KB, van der Korput HA, Ehren-van Eekelen CC, Sikes RA, Fasciana C, Chung LW, Trapman J. 1997a. A 6-kb promoter fragment mimics in transgenic mice the prostate-specific and androgen-regulated expression of the endogenous prostate-specific antigen gene in humans. Mol Endocrinol 11:1256-1265.
8. Cleutjens KB, van der Korput HA, van Eekelen CC, van Rooij HC, Faber PW, Trapman J. 1997b. An androgen response element in a far upstream enhancer region is essential for high, androgen-regulated activity of the prostate-specific antigen promoter. Mol Endocrinol 11: 148-161.
9. Duffy MJ. 1996. PSA as a marker for prostate cancer: A critical review. Ann Clin Biochem 33(Pt 6):511-519.
10. Erman B, Cortes M, Nikolajczyk BS, Speck NA, Sen R. 1998. ETS-core binding factor: A common composite motif in antigen receptor gene enhancers. Mol Cell Biol 18:1322-1330.
11. Gergen JP, Butler BA. 1988. Isolation of the Drosophila segmentation gene runt and analysis of its expression during embryogenesis. Genes Dev 2:1179-1193.
12. Ito Y, Miyazono K. 2003. RUNX transcription factors as key targets of TGF-beta superfamily signaling. Curr Opin Genet Dev 13:43-47.
13. Kim WY, Sieweke M, Ogawa E, Wee HJ, Englmeier U, Graf T, Ito Y. 1999. Mutual activation of Ets-1 and AML1 DNA binding by direct interaction of their autoinhibitory domains. EMBO J 18:1609-1620.
14. Komori T, Kishimoto T. 1998. Cbfa1 in bone development. Curr Opin Genet Dev 8:494-499.
15. Lenny N, Meyers S, Hiebert SW. 1995. Functional domains of the t(8;21) fusion protein, AML-1/ETO. Oncogene 11: 1761-1769.
16. Levanon D, Negreanu V, Bernstein Y, Bar-Am I, Avivi L, Groner Y. 1994. AML1, AML2, and AML3, the human members of the runt domain gene-family: cDNA structure, expression, and chromosomal localization. Genomics 23:425-432.
17. Li QL, Ito K, Sakakura C, Fukamachi H, Inoue K, Chi XZ, Lee KY, Nomura S, Lee CW, Han SB, Kim HM, Kim WJ, Yamamoto H, Yamashita N, Yano T, Ikeda T, Itohara S, Inazawa J, Abe T, Hagiwara A, Yamagishi H, Ooe A, Kaneda A Sugimura T, Ushijima T, Bae SC, Ito Y. 2002. Causal relationship between the loss of RUNX3 expression and gastric cancer. Cell 109:113-124.
18. Lilja H. 2003. Biology of prostate-specific antigen. Urology 62:27-33.
19. Lutterbach B, Westendorf JJ, Linggi B, Isaac S, Seto E, Hiebert SW. 2000. A mechanism of repression by acute myeloid leukemia-1, the target of multiple chromosomal translocations in acute leukemia. J Biol Chem 275:651-656.
20. Melnikova IN, Crute BE, Wang S, Speck NA 1993. Sequence specificity of the core-binding factor. J Virol 67: 2408-2411.
21. Meyers S, Downing JR, Hiebert SW. 1993. Identification of AML-1 and the (8;21) translocation protein (AML-1/ETO) as sequence-specific DNA-binding proteins: The runt homology domain is required for DNA binding and protein-protein interactions. Mol Cell Biol 13:6336-6345.
22. Meyers S, Lenny N, Hiebert SW. 1995. The t(8;21) fusion protein interferes with AML-IB-dependent transcriptional activation. Mol Cell Biol 15:1974-1982.
23. Meyers S, Lenny N, Sun W, Hiebert SW. 1996. AML-2 is a potential target for transcriptional regulation by the t(8;21) and t(12;21) fusion proteins in acute leukemia. Oncogene 13:303-312.
24. Miyoshi H, Shimizu K, Kozu T, Maseki N, Kaneko Y, Ohki M. 1991. t(8;21) breakpoints on chromosome 21 in acute myeloid leukemia are clustered within a limited region of a single gene, AML1. Proc Natl Acad Sci USA 88:10431-10444.
25. Oettgen P, Finger E, Sun Z, Akbarali Y, Thamrongsak U, Boltax J, Grall F, Dube A, Weiss A, Brown L, Quinn G, Kas K, Endress G, Kunsch C, Libermann TA. 2000. PDEF, a novel prostate epithelium-specific ets transcription factor, interacts with the androgen receptor and activates prostate-specific antigen gene expression. J Biol Chem 275:1216-1225.
26. Ogawa E, Inuzuka M, Maruyama M, Satake M, Naito-Fujimoto M, Ito Y, Shigesada K. 1993. Molecular cloning and characterization of PEBP2 beta, the heterodimeric partner of a novel Drosophila runt-related DNA binding protein PEBP2 alpha. Virology 194:314-331.
27. Okuda T, van Deursen J, Hiebert SW, Grosveld G, Downing JR. 1996. AML1, the target of multiple chromosomal translocations in human leukemia, is essential for normal fetal liver hematopoiesis. Cell 84:321-330.
28. Oshimo Y, Oue N, Mitani Y, Nakayama H, Kitadai Y, Yoshida K, Ito Y, Chayama K, Yasui W. 2004. Frequent loss of RUNX3 expression by promoter hypermethylation in gastric carcinoma. Pathobiology 71:137-143.
29. Otto F, Kanegane H, Mundlos S. 2002. Mutations in the RUNX2 gene in patients with cleidocranial dysplasia. Hum Mutat 19:209-216.
30. Riegman PH, Vlietstra RJ, van der Korput JA, Brinkmann AO, Trapman J. 1991. The promoter of the prostate-specific antigen gene contains a functional androgen responsive element. Mol Endocrinol 5:1921-1930.
31. Sasaki K, Yagi H, Bronson RT, Tominaga K, Matsunashi T, Deguchi K, Tani Y, Kishimoto T, Komori T. 1996. Absence of fetal liver hematopoiesis in mice deficient in transcriptional coactivator core binding factor beta. Proc Natl Acad Sci USA 93:12359-12363.
32. Schuur ER, Henderson GA, Kmetec LA, Miller JD, Lamparski HG, Henderson DR. 1996. Prostate-specific antigen expression is regulated by an upstream enhancer. J Biol Chem 271:7043-7051.
33. Strom DK, Nip J, Westendorf JJ, Linggi B, Lutterbach B, Downing JR, Lenny N, Hiebert SW. 2000. Expression of the AML-1 oncogene shortens the G(1) phase of the cell cycle. J Biol Chem 275:3438-3445.
34. Wang SW, Speck NA. 1992. Purification of core-binding factor, a protein that binds the conserved core site in murine leukemia virus enhancers. Mol Cell Biol 12:89-102.
35. Wang Q, Stacy T, Binder M, Marin-Padilla M, Sharpe AH, Speck NA. 1996a. Disruption of the Cbfa2 gene causes necrosis and hemorrhaging in the central nervous system and blocks definitive hematopoiesis. Proc Natl Acad Sci USA 93:3444-3449.
36. Wang Q, Stacy T, Miller JD, Lewis AF, Gu TL, Huang X, Bushweller JH, Bories JC, Alt FW, Ryan G, Liu PP, Wynshaw-Boris A, Binder M, Marin-Padilla M, Sharpe AH, Speck NA. 1996b. The CBFbeta subunit is essential for CBFalpha2 (AML1) function in vivo. Cell 87:697-708.
37. Wang C, Yeung F, Liu PC, Attar RM, Geng J, Chung LW, Gottardis M, Kao C. 2003. Identification of a novel transcription factor, GAGATA-binding protein, involved in androgen-mediated expression of prostate-specific antigen. J Biol Chem 278:32423-32430.
38. Wotton D, Ghysdael J, Wang S, Speck NA, Owen MJ. 1994. Cooperative binding of Ets-1 and core binding factor to DNA. Mol Cell Biol 14:840-850.
39. Yeung F, Law WK, Yeh CH, Westendorf JJ, Zhang Y, Wang R, Kao C, Chung LW. 2002. Regulation of human osteocalcin promoter in hormone-independent human prostate cancer cells. J Biol Chem 277:2468-2476.